Celldex Therapeutics, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016. Celldex is a clinical-stage biopharmaceutical company developing immunotherapies, including glembatumumab vedotin, varlilumab, CDX-1401, CDX-301 and CDX-014. The unaudited interim statements cover the company and its wholly owned subsidiary.
Financial overview
| Metric | Q1 2016 | Q1 2015 or comparison |
|---|---|---|
| Revenue | $1.3 million | $0.5 million; up $0.8 million, or 168% |
| Research and development expense | $27.4 million | $25.1 million; up 9% |
| General and administrative expense | $9.3 million | $6.1 million; up 53% |
| Total operating expense | $37.0 million | $31.5 million; up 18% |
| Operating loss | $35.7 million | $31.0 million |
| Net loss | $34.7 million; $0.35 per share | $30.2 million; $0.33 per share |
| Net cash used in operating activities | $34.9 million | $32.6 million |
| Cash, cash equivalents and marketable securities | $254.0 million at March 31 | $289.9 million at December 31, 2015 |
Revenue remained small relative to operating costs; the filing does not report a gross margin. Investment and other income was $1.0 million, versus $0.8 million a year earlier. Cash and cash equivalents were $63.0 million and marketable securities were $191.0 million at quarter-end. Total assets were $301.9 million and total liabilities were $41.9 million. The filing does not clearly report a conventional borrowings or debt balance; liabilities include deferred revenue, deferred tax, deferred income from sale of tax benefits and other items.
Cash and securities declined by approximately $35.9 million from year-end. Operating activities used $34.9 million; investing activities provided $25.5 million, primarily reflecting net maturities and sales of securities; financing activities provided $0.3 million. Q1 2015 financing included $188.8 million of net proceeds from a public offering, so the periods’ financing cash flows are not directly comparable.
Material changes and operating developments
- Net loss increased $4.5 million year over year, principally because R&D and G&A expenses rose; higher revenue partly offset the increase.
- R&D spending rose 9%, with program costs increasing for varlilumab and CDX-301, among others. G&A rose 53%, reflecting higher stock compensation, headcount and commercial-planning costs.
- On March 7, 2016, Celldex discontinued the Phase 3 ACT IV Rintega study after an independent monitoring board concluded it was unlikely to meet its overall-survival endpoint. Rintega and control arms performed similarly (hazard ratio 0.99; median overall survival 20.4 versus 21.1 months). The company said it did not expect substantial additional Rintega costs.
- METRIC, a randomized Phase 2b glembatumumab vedotin study in triple-negative breast cancer, was enrolling; the company’s goal was to complete enrollment by year-end 2016. It expected to present single-agent melanoma study data in the second half of 2016.
- The Phase 2 portion of the varlilumab–nivolumab study opened to enrollment in April 2016. The company reported acceptable safety in Phase 1 and preliminary biomarker observations; these were early findings, not established evidence of clinical benefit.
- In April 2016, after quarter-end, Celldex entered a research and collaboration agreement with an undisclosed private company and paid $3.5 million for research support and an investment.
Liquidity, outlook and risks
Management stated that quarter-end cash, equivalents and securities were sufficient to fund planned operations through the first half of 2018. The financial-statement note separately says resources would cover estimated working-capital requirements and planned operations for at least the next 12 months. These are management estimates, not assured outcomes. The company may seek additional capital through partnerships, licensing, business combinations, debt or equity; availability and terms are uncertain, and equity financing could dilute shareholders.
Management expected operating cash use and product-development expense to decrease over the following 12 months, mainly because of the Rintega discontinuation, partly offset by increased spending on glembatumumab vedotin and varlilumab. It expected G&A expense to decline as Rintega planning costs fell, while investment income was expected to decrease. No formal revenue or earnings guidance was provided.
Key risks include clinical-trial safety and efficacy outcomes, regulatory approval, trial costs and enrollment, ability to finance development, reliance on collaborators and suppliers, competition, and intellectual-property challenges. The filing reported no material changes to previously disclosed risk factors. New Jersey tax-benefit sale agreements require the company to maintain a New Jersey operating base for five years or repay benefits pro rata for uncompleted years. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether available cash and securities support the stated operating runway, especially given quarterly operating cash use of $34.9 million and the differing runway wording in the filing.
- Enrollment, timing and results for METRIC and other key clinical programs, and whether preliminary varlilumab combination findings translate into clinical benefit.
- Financial and operational consequences of ACT IV’s discontinuation, including any remaining Rintega obligations or costs.
- Future capital requirements and the availability, timing and terms of potential financing or collaboration agreements.
- The $3.5 million post-quarter-end collaboration payment and investment, and compliance with the New Jersey tax-benefit agreement’s operating-location condition.